Mineralocorticoid receptor antagonists (MRAs) are a prospective therapeutic option in DKD because of the activation of mineralocorticoid receptor in podocytes, mesangial cells, inflammatory cells, fibroblasts, and vascular cells (Barrera-Chimal et al., 2022). This evidence concerns the gene NR3C2 and diabetic kidney disease.